May 27, 2020
Wize Pharma's Strategic Transaction Partner Bonus BioGroup to Present MesenCure Data at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting on May 28-29, 2020
May 18, 2020
Wize Pharma's Strategic Transaction Partner Bonus BioGroup Reports Successful Treatment of Acute Pneumonia in Preclinical COVID-19 Model
Apr 21, 2020
Wize Pharma's Strategic Transaction Partner Bonus Biogroup Initiates Preclinical Study for Treatment of Respiratory Distress in COVID-19 Patients
Feb 20, 2020
Wize Pharma Completes Bonus BioGroup Strategic Transaction
Jan 21, 2020
Wize Pharma Completes Patient Enrollment In Phase IV Study Of LO2A for the Treatment of Dry Eye Syndrome in Patients With Sjögren's Syndrome
Dec 03, 2019
Wize Pharma Lenders Convert $760,000 of Loans Into Equity
Sep 09, 2019
Wize Pharma Enters Exclusive License Agreement for Ophthalmic Non-viral Gene Therapy Technology
Jul 08, 2019
Wize Pharma Retains Life Science Advisory Firm Lighthouse BioPartners to Support Potential Pharma Partnership Deals for its Lead Asset LO2A
Jun 28, 2019
Wize Pharma Completes Milestone for Joint Venture With Cannabics Pharmaceuticals; Companies to Develop Cannabinoid Ophthalmic Treatments
May 21, 2019
Wize Pharma Issues Letter to Shareholders
Apr 30, 2019
Wize Pharma to Present at ThinkEquity Conference on May 2, 2019 in New York City
Apr 29, 2019
Wize Pharma Announces Positive Results in First Controlled Study of Treatment for Dry Eye Syndrome in Patients With Conjunctivochalasis
Apr 24, 2019
Wize Pharma's CEO Noam Danenberg Increases Stake in Company
Apr 23, 2019
Wize Pharma Appoints Mark Sieczkarek as Chairman of the Board, Noam Danenberg to Become Chief Executive Officer
Mar 06, 2019
Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics
Feb 07, 2019
Wize Pharma, Inc. Signs Joint Venture With Cannabics, to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions
Feb 07, 2019
Cannabics Pharmaceuticals and Wize Pharma to Form Joint Venture to Develop Cannabinoid Based Ophthalmic Therapeutics
Jan 10, 2019
Wize Pharma, Inc. Announces Publication of Peer Reviewed LOA2 Data on Treatment of Moderately Severe Sjögren's Syndrome-Related Dry Eye
Nov 20, 2018
Wize Pharma Announces Meeting Its Phase II Study Primary Objective to Demonstrate LO2A Effectively Treats Dry Eye Syndrome in Patients with Conjunctivochalasis
Oct 24, 2018
Wize Pharma, Inc. Announces Closing of $4.45 Million Private Placement